# Beijing Immunochina Medical Science & trials: 27 (2026)

ClinicalTrials.gov lists 27 trials with Beijing Immunochina Medical Science & Technology Co., Ltd. as lead sponsor, 7 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Beijing Immunochina Medical Science & Technology Co., Ltd.: 27 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/beijing-immunochina-medical-science-and-technology-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 12, 2026 | NCT07406984 | Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Not yet recruiting | Adenocarcinoma of Gastric, Adenocarcinoma of Esophagogastric Junction | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406984) |
| March 20, 2025 | NCT06886919 | Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Not yet recruiting | Difficult to Treat Systemic Lupus Erythematosus | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06886919) |
| February 28, 2025 | NCT06852573 | Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06852573) |
| December 5, 2024 | NCT06718738 | Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Recruiting | Colorectal Cancer (CRC) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06718738) |
| November 15, 2024 | NCT06691308 | WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Not yet recruiting | Recurrent or Progressive Glioblastoma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06691308) |
| November 15, 2024 | NCT06690359 | IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Not yet recruiting | IgA Nephropathy, Membranous Nephropathy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06690359) |
| May 14, 2024 | NCT06412458 | IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | Refractory Osteosarcoma, Recurrent Osteosarcoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06412458) |
| January 17, 2024 | NCT06209671 | INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | Leukemia, B-cell | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06209671) |
| July 29, 2022 | NCT05480501 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute... | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Unknown | Leukemia | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05480501) |
| July 28, 2022 | NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Unknown | Multiple Myeloma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05478343) |
| April 4, 2022 | NCT05309213 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute... | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1/2 | Unknown | Leukemia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05309213) |
| March 18, 2022 | NCT05287165 | Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Unknown | Advanced Solid Tumors, Digestive System Neoplasms, Pancreatic Cancer Resectable, Colorectal (Colon or Rectal) Cancer | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05287165) |
| March 11, 2022 | NCT05275062 | Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic... | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Unknown | Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05275062) |
| December 13, 2021 | NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1/2 | Unknown | Lymphoma, Lymphoma, Mantle-Cell, Neoplasms by Histologic Type, Neoplasms, Lymphoproliferative Disorders | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05155215) |
| November 17, 2021 | NCT05123209 | Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | Liver Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05123209) |
| November 11, 2021 | NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1/2 | Unknown | Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05117138) |
| July 6, 2021 | NCT04951141 | Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors | Beijing Immunochina Medical Science & Technology Co., Ltd. | Early phase 1 | Unknown | Hepatocellular Carcinoma , Cholangiocarcinoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04951141) |
| February 23, 2021 | NCT04766840 | Donor-derived CAR-T Cells in the Treatment of AML Patients | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | AML | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04766840) |
| September 3, 2020 | NCT04537442 | Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory... | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | Multiple Myeloma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04537442) |
| June 19, 2020 | NCT04440436 | Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1/2 | Recruiting | NHL | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04440436) |
| April 7, 2020 | NCT04336501 | Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation | Beijing Immunochina Medical Science & Technology Co., Ltd. | Not applicable | Unknown | Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04336501) |
| July 13, 2018 | NCT03585517 | Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Completed | AML | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03585517) |
| May 24, 2018 | NCT03535753 | Safety and Efficacy Evaluation of Decitabine With R-GDP | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | NHL | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03535753) |
| May 17, 2018 | NCT03528421 | Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | Non Hodgkin Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03528421) |
| November 17, 2017 | NCT03344705 | Safety and Efficacy Evaluation of IM19 Cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 | Unknown | Hematological Malignancies | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03344705) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 8 |
| Phase 1 | 12 |
| Phase 1/2 | 6 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 18 |
| Not yet recruiting | 5 |
| Recruiting | 2 |
| Completed | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia | 5 |
| Liver Neoplasms | 2 |
| Burkitt Lymphoma | 2 |
| Multiple Myeloma | 2 |
| Recurrence | 2 |
| Melanoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Glomerulonephritis, IGA | 1 |
| Glomerulonephritis, Membranous | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Hematologic Neoplasms | 1 |
| Lymphoma | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Neoplasms by Histologic Type | 1 |
| Neoplasms | 1 |
| Lymphoproliferative Disorders | 1 |
| Osteosarcoma | 1 |
| Leukemia, B-Cell | 1 |
| Digestive System Neoplasms | 1 |
| Colonic Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Disability law firms in the United States](https://specstream.ai/data/businesses/disability-law-firms/united-states)
- [Business brokers in the United States](https://specstream.ai/data/businesses/business-brokers/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [Translation and interpreting companies in the United States](https://specstream.ai/data/businesses/translation-and-interpreting-companies/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
- [Patent law firms in the United States](https://specstream.ai/data/businesses/patent-law-firms/united-states)
